SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZTC -- Ignore unavailable to you. Want to Upgrade?

To: H. Bradley Toland, Jr. who wrote (614)9/16/1999 5:57:00 PM
From: kinkblot  Respond to of 752
 
Hi bt, I'm glad to hear that about Remicade.

I've only followed Folkman casually before now, but he has always come across to me as a genuine pioneer. Since some transgenically produced aaATIII from Genzyme has already been used in the preclinical studies, it's reasonable to hope that reproducing the results will be more straightforward than was the case with Folkman's other inhibitors.

Will


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News